Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease

Journal of Nuclear Medicine

Volumn 44, Issue 5, 2003, Pages 663-670

  Prunier, Caroline ^a   Payoux, Pierre ^b   Guilloteau, Denis ^a   Chalon, Sylvie ^a   Giraudeau, Bruno ^c   Majorel, Cynthia ^b   Tafani, Mathieu ^b   Bezard, Erwan ^d   Esquerré, Jean Paul ^b   Baulieu, Jean Louis ^a  

^a CHU BRETONNEAU   (France)

^b CHU PURPAN   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d CNRS   (France)

Author keywords

123I PE2I; Diagnosis; Logan plot; Parkinson's disease; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROP 2 ENYL) 2BETA CARBOMETHOXY 3BETA (4' METHYLPHENYL)NORTROPANE; NORTROPANE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; CARRIER PROTEIN; DIAGNOSTIC AGENT; MEMBRANE PROTEIN; N (3 IODOPROP 2 ENYL) 2 BETA CARBOMETHOXY 3 (4 METHYLPHENYL)NORTROPANE; N-(3-IODOPROP-2-ENYL)-2-BETA-CARBOMETHOXY-3-(4-METHYLPHENYL)NORTROPANE; NERVE PROTEIN; RADIOACTIVE IODINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; IMAGING; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS; METABOLISM; MIDDLE AGED; SCINTISCANNING;

AGED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NORTROPANES; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0038282733     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hoehn HM, Yahr MD. Parkinsonism onset, progression and mortality. Neurology. 1967;17:427-442.
2. Jellinger KA Neurodegenerative disorders with extrapyramidal features: a neuropathological overview. J Neural Transm. 1995;46(suppl) 33-57.
3. Gibb WRG, Lees AJ Anatomy, pigmentation, ventral and dorsal surpopulations of the substantia nigra, and differential cell death in Parkinson's disease J Neurol Neurosurg Psychiatry. 1991;54:388-396.
4. Pollack P, Fraix V, Krack P, et al Treatment results: Parkinson's disease. Mov Disord. 2002;17(suppl 3):S75-S83.
5. Riederer P, Sian J, Gerlach M Is there neuroprotection in Parkinson syndrome? J Neurol. 2000;247(suppl 4):IV8-IV11.
6. Riederer P, Brucke T, Muller T, Schwartz A, Storch A, Winner B. Workshop II. "Neuroprotection" - the Lugano consensus J Neurol. 2000;247(suppl 4):IV36-IV37.
7. Booij J, Tissingh G, Winogrodzka A, van Royen EA Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171-182.
8. Thobois S, Guillouet S, Broussolle E Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiol Clin. 2001;31:321-340.
9. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589-598.
10. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 1990;47:1290-1298.
11. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackoviak SJ Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Brain 1993;116:853-867
12. Emond P, Garreau L, Chalon S, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2b-carboxymethoxy-3b-(4′-iodopheny1) nortropane and N-(3-iodoprop-2E-enyl)-2b-carboxymethoxy-3b-(3′,4′- disubstituted phenyl) nortropane: new high-affinity and selective compounds for the dopamine transporter J Med Chem. 1997;40:1366-1372
13. Chalon S, Garreau L, Emond P, et al Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl) nortropane as a selective and potent inhibitor of the neuronal dopamine transporter J Pharmacol Exp Ther 1999;291:648-654.
14. Guilloteau D, Emond P, Baulieu JL, et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β- carbomethoxy-3β-(4′-methylphenyl) nortropane (PE2I). Nucl Med Biol. 1998;25:331-337.
15. 11C]PE2I. a selective radioligand for PET-examination of the dopamine transporters in human brain [abstract]. Eur J Nucl Med 2000;27:928
16. Farde L, Hall H, Ehrin E, et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-261.
17. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840
18. Kuikka JT, Baulieu JL, Hiltunen J, et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging Eur J Nucl Med. 1998;25:531-534.
19. 123I) PE2I binding to dopamine transporters with SPET. Eur J Nucl Med. 2002;29:623-631
20. Gibb WRG, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology. 1988;38:1402-1406
21. Quinn NP. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford, U.K.: Butterworth-Heinemann, 1994:262-281.
22. Litvan I, Mangone CA, McKee A, et al Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;61:615-623.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
24. Folstein MF, Folstein SE, McHugh PR. "Mini Mental Test": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198
25. 123I-PE2I a new specific dopamine transporter ligand, by kinetic approach in healthy and MPTP-treated monkeys [abstract]. Eur J Nucl Med. 2001,28.1010 (OS190).
26. 123I]PE2I. Neuroimage. 1999;9:108-116.
27. 123I]β-CIT). high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem. 1991;34:3144-3146.
28. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982-994.
29. Kim SE, Lee WY, Choe YS, Kim JH. SPECT measurement of iodine-123-β-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol Res. 1999;21:255-261.
30. 123I]-β-CIT. J Nucl Med. 1996;37:1129-1133.
31. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140
32. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's disease. J Nucl Med. 1998;39:1500-1508
33. Madras BK, Gracz LM, Fahey MA, et al Altropane, a SPECT or PET imaging probe for dopamine neurons: III Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse. 1998;29:116-127.
34. 123I]IACFT. J Nucl Med. 2000;41:1086-1092.
35. Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen GM. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med. 1993;34:2076-2084.
36. 123I-iodolisuride SPET. Nucl Med Commun. 1999;20:77-84.
37. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231-237
38. 123I]β- CIT and SPECT: an exploratory study. Mayo Clin Proc. 1999;74:681-685.
39. Pirker W, Djamshidian S, Asenbaum S, et al Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord. 2002;17:45-53.